← Back to Clinical Trials
Recruiting NCT06933836

NCT06933836 DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06933836
Status Recruiting
Phase
Sponsor Barnet Dulaney Perkins Eye Centers
Condition Open Angle Glaucoma (OAG)
Study Type OBSERVATIONAL
Enrollment 55 participants
Start Date 2025-03-31
Primary Completion 2027-11-30

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
DSLT enables newly diagnosed patients to remain well controlled and off medications

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 55 participants in total. It began in 2025-03-31 with a primary completion date of 2027-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.

Eligibility Criteria

Inclusion Criteria: * Primary open angle glaucoma * Patients age 30 or greater with an IOP of 18-26 mmHg * Mild to moderate POAG patients (mild or moderate according to the AAO PPP Guidelines) * DSLT procedure Exclusion Criteria: * History of prior glaucoma treatment - this includes past medication use (in either eye), previous lasers or incisional surgery * Angle closure patients * Ocular Hypertension * Baseline VF MD of worse than -12dB * Uncontrolled systemic microvascular disease (eg. HTN, DM) * Subjects with peri-limbal findings (e.g. melanosis, tumors, extensive pterygium, significant senile arcus and pterygium)

Contact & Investigator

Central Contact

Derek J Arnson, Master of Education

✉ derek.arnson@researchavp.com

📞 4804201005

Principal Investigator

Christine Funke, Medical Doctor

PRINCIPAL INVESTIGATOR

Barnet Dulaney Perkins Eye Centers

Frequently Asked Questions

Who can join the NCT06933836 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, studying Open Angle Glaucoma (OAG). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06933836 currently recruiting?

Yes, NCT06933836 is actively recruiting participants. Contact the research team at derek.arnson@researchavp.com for enrollment information.

Where is the NCT06933836 trial being conducted?

This trial is being conducted at Mesa, United States.

Who is sponsoring the NCT06933836 clinical trial?

NCT06933836 is sponsored by Barnet Dulaney Perkins Eye Centers. The principal investigator is Christine Funke, Medical Doctor at Barnet Dulaney Perkins Eye Centers. The trial plans to enroll 55 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology